Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4403-4407

  Keel, R A ^a   Tessier, P R ^b   Crandon, J L ^b   Nicolau, D P ^b  

^a California Northstate College of Pharmacy   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; TEDIZOLID;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIOSTASIS; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITY; FEMALE; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMULATION; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL SKIN INFECTIONS; TETRAZOLES; THIGH;

EID: 84864390984     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00122-12     Document Type: Article

References (36)

1. Andes D, van Ogtrop ML, Peng J, Craig WA. 2002. In vivo pharmacodynamics of a new oxazolidinone (Linezolid). Antimicrob. Agents Chemother. 46:3484 -3489.
2. Bien P, et al. 2008. Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic, abstr. F1-2063. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
3. Brown SD, Traczewski MM. 2010. Comparative in vivo antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretative criteria, and quality control ranges. Antimicrob. Agents Chemother. 54:2063-2069.
4. Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. 2006. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother. 50:2455-2463. (Pubitemid 43993186)
5. Clinical and Laboratory Standards Institute (CLSI). 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically approved standard, 8th edition. M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
6. De Anda C, Das A, Fang E, Prokocimer P. 2011. Acute bacterial skin and skin structure infection (ABSSSI) dose-ranging phase 2 tedizolid phosphate (TR-701) study: assessment of efficacy with new FDA guidance, abstr. L1-1496. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
7. Drusano GL, et al. 2011. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob. Agents Chemother. 55:5300-5305.
8. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144. (Pubitemid 44631403)
9. Housman ST, et al. 2011. Pulmonary disposition of torezolid following 200 mg once-daily oral tedizold phosphate in healthy volunteers, abstr. A1-1747. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Howden BP, et al. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528. (Pubitemid 38250962)
11. Hsu DI, et al. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378-385.
12. Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M. 2009. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J. Antimicrob. Chemother. 63:716-720.
13. Jones RN. 2006. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42:S13-S24. (Pubitemid 41832061)
14. LaPlante KL, Leonard SL, Andes DR, Craig WA, Rybak MJ. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim- sulfamethoxazole, and vancomycin against communityassociated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob. Agents Chemother. 52:2156-2162. (Pubitemid 351758553)
15. Livermore DM, Mushtaq S, Warner M, Woodford N. 2009. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J. Antimicrob. Chemother. 63:713-715.
16. Locke JB, Hilgers M, Shaw KJ. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 53:5265-5274.
17. Locke JB, Hilgers M, Shaw KJ. 2009. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob. Agents Chemother. 53:5275-5278.
18. Locke JB, et al. 2010. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob. Agents Chemother. 54:5337-5343.
19. Louie A, Lui W, Kulawy R, Drusano GL. 2011. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob. Agents Chemother. 55:3453-3460.
20. Louie A, et al. 2009. Defining the impact of granulocytes on the kill of methicillin-resistant Staphylococcus aureus (MRSA) by the new oxazolidinone prodrug TR-701, abstr. A1-1935. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
21. MacGowan AP. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl 2):ii17-ii25. (Pubitemid 36622108)
22. Mason EO, et al. 2009. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J. Clin. Microbiol. 47:1628-1630.
23. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548-553. (Pubitemid 36158080)
24. Neoh H, et al. 2007. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 6:13.
25. Pichereau S, et al. 2009. Comparative pharmacodynamics of novel oxazolidinone, torezolid phosphate (TR-701), against S. aureus in the neutropenic murine pneumonia model, abstr A1-1939. Abstr 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
26. Prokocimer P, et al. 2011. Phase 2, randomized, double-blind, doseranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592.
27. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. 2003. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42:1411-1423. (Pubitemid 38054365)
28. Rhee KY, Gardiner DF, Charles M. 2005. Decreasing in-vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin. Infect. Dis. 40:1705-1706. (Pubitemid 40720831)
29. Rybak M, et al. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
30. Sader HS, et al. 2009. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 53:4127- 4132.
31. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. 2009. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 53:3236-3239.
32. Shaw KJ, et al. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52:4442-4447.
33. Soriano A, et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200. (Pubitemid 351269157)
34. Steinkraus G, White R, Friedrich L. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794. (Pubitemid 47434257)
35. Stevens DL, et al. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406. (Pubitemid 41581713)
36. Tobin CM, Sunderland J, White LO, MacGowan AP. 2001. A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. J. Antimicrob. Chemother. 48:605-608. (Pubitemid 33100305)